Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile

•This paper summarizes the most current state of knowledge on lurasidone.•Pharmacological properties (receptor binding profile, pharmacokinetic profile, interactions and toxicity).•Preclinical (animal) data.•Clinical utility in patients with schizophrenia and bipolar depression. The aim of this pape...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacological reports 2016-08, Vol.68 (4), p.748-755
Main Authors: Jaeschke, Rafał R., Sowa-Kućma, Magdalena, Pańczyszyn-Trzewik, Patrycja, Misztak, Paulina, Styczeń, Krzysztof, Datka, Wojciech
Format: Article
Language:English
Subjects:
Animals
Antipsychotic Agents - adverse effects
Antipsychotic Agents - pharmacokinetics
Antipsychotic Agents - pharmacology
Antipsychotic Agents - therapeutic use
Atypical antipsychotics
Bipolar disorder
Bipolar Disorder - drug therapy
Drug Safety and Pharmacovigilance
Humans
Hyperprolactinemia - chemically induced
Lurasidone
Lurasidone Hydrochloride - adverse effects
Lurasidone Hydrochloride - pharmacokinetics
Lurasidone Hydrochloride - pharmacology
Lurasidone Hydrochloride - therapeutic use
Pharmacotherapy
Pharmacy
Radioligand Assay
Review Article
Schizophrenia
Schizophrenia - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•This paper summarizes the most current state of knowledge on lurasidone.•Pharmacological properties (receptor binding profile, pharmacokinetic profile, interactions and toxicity).•Preclinical (animal) data.•Clinical utility in patients with schizophrenia and bipolar depression. The aim of this paper was to review the up-to-date evidence base on pharmacology and clinical properties of lurasidone. Lurasidone is an atypical antipsychotic, approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar depression. Lurasidone exhibits both an antipsychotic and antidepressant action. Based on its pharmacodynamics profile, it is believed that the drug's clinical action is mediated mainly through the D2, 5-HT2A and 5-HT7 receptors inhibition. In patients with schizophrenia the recommended dose range is 40–80mg/day. In bipolar depression broader dosage ranges (20–120mg/day) were found to be effective. In terms of side effects, higher rates of akathisia, parkinsonism and hyperprolactinemia were observed in individuals receiving lurasidone (as compared to patients treated with other atypical antipsychotics). On the other hand, treatment with lurasidone yields relatively lower risk for developing sedation or overweight/obesity.
ISSN:1734-1140
2299-5684
DOI:10.1016/j.pharep.2016.04.002